Applications of Cytosorb in clinical practice
Paweł Kutnik 1  
More details
Hide details
Student’s Scientific Association, II Department of Anaesthesiology and Intensive Care, Medical University, Lublin, Poland
II Department of Anaesthesiology and Intensive Care, Medical University, Lublin, Poland
Paweł Kutnik   

Student's Scientific Association, II Department of Anaesthesiology and Intensive Care, Medical University of Lublin, Lublin, Poland.
Introduction and objective:
Cytososorb is haemadsorption device approved in the European Union in 2011 for cytokine adsorption. Recently, in 2018, new indications for the device use have been added, including bilirubin and myoglobin removal. This study aimed to present the results of studies pertaining to Cytosorb use in clinical practice. In subsequent sections of this review, indications for Cytosorb therapy and clinical relevance of presented evidence are listed.

State of knowledge:
In clinical practice, Cytosorb has been reported as one of potential supportive therapies in patients with septic shock. There is evidence of significant reduction of interleukin 6 and vasopressors when Cytosorb is implemented. However, the decreased mortality after Cytosorb has yet to be reported. Besides cytokine adsorption, Cytosorb also collects drugs, a property that can have a beneficial effect on acute drug poisoning (anticoagulants). However, Cytosorb lowers the plasma concentration of some antibiotics which might affect the outcome of patients in septic shock. The haemadsorption device has also been researched in cardiac patients, and some reports suggest a reduced need for vasopressors and blood transfusions when therapy is installed during surgery. Other indications for Cytosorb are also reported, especially the effectiveness in decreasing bilirubin serum concentrations as treatment or bridge therapy, without affecting the albumins. Cytosorb might also be the last resort treatment in acquired haemophagocytic lymphohistiocytosis.

The evidence supporting the use of CytoSorb remains elusive. There is lack of large prospective studies which could provide definitive answers about the place of Cytosorb in clinical practice. There are no reports of safety and feasibility issues in all presented studies.

Malard B, Lambert C, Kellum JA. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med Exp. 2018; 6(1): 12.
Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus antiinflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis. 2000; 181(1): 176–180.
David S, Thamm K, Schmidt BMW, Falk CS, Kielstein JT. Effect of extracorporeal cytokine removal on vascular barrier function in a septic shock patient. J Intensive Care. 2017; 5: 12. doi:10.1186/s40560- 017-0208-1.
Gruda MC, Ruggeberg K-G, O’Sullivan P, Guliashvili T, Scheirer AR, Golobish TD, et al. Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb® sorbent porous polymer beads. PLoS ONE 2018; 13(1): e0191676.
Hinz B, Jauch O, Noky T, Friesecke S, Abel P, Kaiser R. CytoSorb, a novel therapeutic approach for patients with septic shock: a case report. Int J Artif Organs. 2015; 38(8): 461–464.
Hawchar F, László I, Öveges N, Trásy D, Ondrik Z, Molnar Z. Extracorporeal cytokine adsorption in septic shock: a proof of concept randomized, controlled pilot study. J Crit Care. 2019; 49: 172–178.
Friesecke S, Stecher SS, Gross S, Felix SB, Nierhaus A. Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study. J Artif Organs 2017; 20: 252–259. https://
Tomescu D, Popescu M, David C, & Dima S. Clinical effects of hemoadsorption with CytoSorb® in patients with severe acute pancreatitis: A case series. Int J Artif Organs 2019; 42(4): 190–193. https://
Friesecke S, Träger K, Schittek GA, Molnar Z, Bach F, Kogelmann K, et al. International registry on the use of the CytoSorb® adsorber in ICU patients: study protocol and preliminary results. Med Klin Intensivmed Notfmed. 2017.
Kogelmann K, Jarczak D, Scheller M, Druner M. Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care 2017; 21(1): 74.
Schädler D, Pausch C, Heise D, Meier-Hellmann A, Brederlau J, Weiler N, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial. PLoS One 2017; 12(10): e0187015. pone.0187015.
Reiter K, Bordoni V, Dall’Olio G, Ricatti MG, Soli M, Ruperti S, et al. In vitro removal of therapeutic drugs with a novel adsorbent system. Blood Purif. 2002; 20(4): 380–388.
König C, Rohr A. C, Frey O. R. Brinkmann A. Roberts J. A. Wichmann D. et al. In vitro removal of anti-infective agents by a novel cytokine adsorbent system. Int J Artif Organs 2019; 42(2): 57–64. https://doi. org/10.1177/0391398818812601.
Paterson IK, Hoyle A, Ochoa G, Baker-Austin C, Taylor NG. Optimising Antibiotic Usage to Treat Bacterial Infections. Sci Rep. 2016; 28(6): 37853.
Opatowski L, Mandel J, Varon E, Boëlle PY, Temime L, Guillemot D. Antibiotic dose impact on resistance selection in the community: a mathematical model of beta-lactams and Streptococcus pneumoniae dynamics. Antimicrob Agents Chemother. 2010; 54(6): 2330–2337.
Zoller M, Döbbeler G, Maier B, Vogeser M, Frey L, Zander J. Can cytokine adsorber treatment affect antibiotic concentrations? A case report. J Antimicrob Chemother. 2015; 70(7): 2169–2171. https://doi. org/10.1093/jac/dkv068.
Poli EC, Simoni C, André P, Buclin T, Longchamp D, Perez M, et al. Clindamycin clearance during Cytosorb® hemoadsorption: A case report and pharmacokinetic study. Int J Artif Organs 2019; 42(5): 258–262.
Giuntoli L, Dalmastri V, Cilloni N, Orsi C, Stalteri L, Demelas V, et al. Severe quetiapine voluntary overdose successfully treated with a new hemoperfusion sorbent. Int J Artif Organs 2019 [ahead of print] https://
Hassan K, Kannmacher J, Wohlmuth P, Budde U, Schmoeckel M, Geidel S. Cytosorb adsorption during emergency cardiac operations in patients at high risk of bleeding. Ann Thorac Surg. 2019; 108(1): 45–51. doi: 10.1016/j.athoracsur.2018.12.032.
Warltier D, Laffey J, Boylan J, Cheng D. The Systemic Inflammatory Response to Cardiac Surgery: Implications for the Anesthesiologist. Anesthesiology 2002; 97(1): 215–252.
Träger K, Skrabal C, Fischer G, Datzmann T, Schroder J, Fritzler D, et al. Hemoadsorption treatment of patients with acute infective endocarditis during surgery with cardiopulmonary bypass – a case series. Int J Artif Organs. 2017; 40(5): 240–249.
Nemeth E, Kovacs E, Racz K, Soltesz A, Szigeti S, Kiss N, et al. Impact of intraoperative cytokine adsorption on outcome of patients undergoing orthotopic heart transplantation—an observational study. Clin Transpl. 2018; 32(4): e13211.
Gleason TG, Argenziano M, Bavaria JE, Kane LC, Coselli JS, Engelman RM, et al. Hemoadsorption to Reduce Plasma Free Hemoglobin during Cardiac Surgery: Results of REFRESH I Pilot Study. Semin Thorac Cardiovasc Surg 2019 [ahead of print].
Saller T, Hagl C, Woitsch S, Li Y, Niedermayer S, Born F. et al. Haemadsorption improves intraoperative haemodynamics and metabolic changes during aortic surgery with hypothermic circulatory arrest, European Journal of Cardio-Thoracic Surgery(2019). https://doi. org/10.1093/ejcts/ezz074 [ahead of print].
Kühne LU, Binczyk R, Rieß FC. Comparison of intraoperative versus intraoperative plus postoperative hemoadsorption therapy in cardiac surgery patients with endocarditis. Int J Artif Organs 2019; 42(4): 194–200.
Bernardi MH, Rinoesl H, Dragosits K, Ristl R, Hoffelner F, Opfermann P, et al. Effect of hemoadsorption during cardiopulmonary bypass surgery – a blinded, randomized, controlled pilot study using a novel adsorbent. Crit Care. 2016; 20: 96. 1270-0.
Poli EC, Alberio L, Bauer-Doerries A, Marcucci C, Roumy A, Kirsch M, et al. Cytokine clearance with CytoSorb® during cardiac surgery: a pilot randomized controlled trial. Crit Care. 2019; 23(1): 108. https://
Hartmann J, Harm S. Removal of bile acids by extracorporeal therapies: an in vitro study. Int J Artif Organs 2018; 41(1): 52–57. https://doi. org/10.5301/ijao.5000643.
Gemelli C, Cuoghi A, Magnani S, Atti M, Ricci D, Siniscalchi A, et al. Removal of Bilirubin with a New Adsorbent System: In Vitro Kinetics. Blood Purif. 2019; 47(1–3): 10–15.
Singh A, Mehta Y, Trehan N. Bilirubin Removal Using CytoSorb Filter in a Cardiac Surgical Patient. J Cardiothorac Vasc Anesth. 2019; 33(3): 881–883.
Faltlhauser A, Kullmann F. Use of Hemoadsorption in a Case of Severe Hepatic Failure and Hyperbilirubinemia. Blood Purif. 2017; 44(2): 98–99.
Dhokia VD, Madhavan D, Austin A, Morris CG. Novel use of Cytosorb™ haemadsorption to provide biochemical control in liver impairment. J Intensive Care Soc. 2019; 20(2): 174–181. https://doi. org/10.1177/1751143718772789.
Piwowarczyk P, Kutnik P, Potręć-Studzińska B, Sysiak-Sławecka J, Rypulak E, Borys M, et al. Hemoadsorption in isolated conjugated hyperbilirubinemia after extracorporeal membrane oxygenation support. Cholestasis of sepsis: A case report and review of the literature on differential causes of jaundice in ICU patient. Int J Artif Organs 2019; 42(5): 263–268.
Buttner S, Patyna S, Koch B, Finkelmeier F, Geiger H, Sarrazin C, et al. Application of Hemoadsorption in a Case of Liver Cirrhosis and Alcohol-Related Steatohepatitis with Preexisting Hepatitis C Infection. Blood Purif. 2017; 44(1): 30–31.
Cirstoveanu CG, Barascu I, Mc Kenzie Stancu S. Hemadsorption with Adult CytoSorb® in a Low Weight Pediatric Case. Case Rep Crit Care. 2017; 2017: 6987167.
Calabrò MG, Febres D, Recca G, Lembo R, Fominskiy E, Scandroglio AM, et al. Blood Purification With CytoSorb in Critically Ill Patients: Single-Center Preliminary Experience. Artif Organs 2019; 43(2): 189
Frimmel S, Hinz M, Schipper J, Bogdanow S, Mitzner S, Koball S. Cytokine adsorption is a promising tool for therapy of hemophagocytic lymphohistiocytosis, Int J Artif Organs 2019. doi: 10.1177/0391398819857444 [ahead of print].
Milella L, Ficarella M. First Application of CVVHDF, Plasmapheresis and “Cytosorb Absorber” to Solve a Pediatric Haemophagocitic Histyocitosis Case. Res Pediatr Neonatol. 2017; 1(2). 10.31031/RPN.2017.01.000510.
Khawaja MR, Manchanda N. Acquired Hemophagocytic Lymphohistiocytosis Among Adults: A Single Center Experience. Blood. 2013; 122(21): 2277.